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Abstract
Aggregation is a critical issue that hampers the development of monoclonal antibody therapeutics 
(Mabs). Traditionally, aggregation is considered a process in which native forms of proteins are 
transformed into an unstable highly associated form through an intermediate formation step. Here 
we describe the unfolding of an anti CD40 antibody using a folding model based on Lumry-Eyring 
nucleated polymerization (LENP) model. This model captures several experimental features of the 
thermal unfolding of this protein as studied by common in situ biophysical techniques such as 
circular dichroism, fluorescence spectroscopy and turbidity measurements. According to this 
model, the unfolding and aggregation of the anti CD40 antibody is determined by several distinct 
steps that include conformational change(s) to generate aggregation prone states, reversible 
oligomer formation, nucleation and growth as well as their kinetics and the formation of higher 
order assemblies/aggregates. Furthermore, the loss of monomer is controlled by both 
thermodynamic (equilibrium unfolding) and kinetic determinants of the unfolding process. This 
approach captures both of these rate-limiting steps. It can be concluded that this approach is 
sensitive to formulation conditions such as protein concentration, changes in buffer conditions, and 
temperature stress. The potential use of this approach in formulation development and stability 
testing of Mabs is discussed.
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Monoclonal antibodies (Mab) constitute an important class of protein therapeutics (1). 
Several Mabs are already in use clinically for various indications with many more in 
different stages of development (2). The efficient development of Mabs as drugs, however, 
poses a number of significant challenges. Due to the desirability of reduced volumes, higher 
concentrations of Mabs need to be formulated. The presence of Mabs at such high 
concentration often leads to physical instability such as aggregation. Analytical 
methodology and approaches that are currently available are often inadequate to study 
proteins at such high concentrations. New analytical approaches are being developed to 
address this issue (3). Objective of this study was to explore the possibility of (i) using 
common in situ analytical methods to capture key events in protein unfolding and (ii) 
developing a suitable folding model to describe routine molecular events that can aid in the 
rational formulation development and stability testing of MABs.
The use of a folding model used in conjunction with various physical techniques in 
formulation development is tested here employing an anti CD40 monoclonal antibody as a 
representative protein. CD40 is a Tumor Necrosis Factor receptor found on several antigen 
presenting cells (4). This family of receptors is essential for mediating several immune and 
inflammatory responses. Anti-CD40 antibodies are potential therapeutic agents for several 
inflammatory disorders and immune system deficiencies. We investigated the unfolding and 
aggregation kinetics of this protein using several biophysical techniques such as circular 
dichroism (CD), fluorescence emission and turbidity measurements. Circular dichroism 
studies provide information about secondary structural changes, while fluorescence emission 
studies are sensitive to changes in tertiary structure. These two studies can be combined with 
turbidity measurements, which provide insight into aggregation processes in response to 
various simulated stress conditions.
Experimental results are incorporated into a folding model based on a Lumry-Eyring 
nucleated polymerization (LENP) model (5). We applied this model, depicted in figure 1, to 
define key steps involved in the unfolding of this Mab, since it captures several of our 
experimental observations. The results suggest that this approach can be useful for rational 
formulation development and stability testing of Mabs.
Materials
Murine Anti-CD40 monoclonal antibody (Lot numbers DSW014071, DSW0108061, Clone 
number 82105) was obtained from R & D Systems as a lyophilized powder containing 5% 
trehalose. The lyophilized powder was reconstituted using sterile PBS as recommended by 
the manufacturer. Reconstituted sample was aliquoted and stored at −70°C to ensure no loss 
of activity. Multiple freeze-thaw cycles were avoided. Buffer salts were either purchased 
from Fisher Scientific (Fair Lawn, NJ) or from Sigma (St. Louis, MO) and were used 
without further purification.
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CD spectra were obtained using a JASCO-715 spectropolarimeter fitted with a Peltier 300 
RTS unit for temperature dependent studies. The instrument was calibrated using d10 
camphor sulphonic acid. The far UV CD spectra for secondary structural analysis were 
acquired in the wavelength range of 207 to 260 nm. The protein concentrations used were 20 
or 400 μg/ml in quartz cuvettes of 10 or 1mm path lengths, respectively. The melting profiles 
were generated by monitoring the ellipticity at 215 or 230 nm over the temperature range of 
20°C–90°C with a 2 min holding time every 5°C. The tertiary structural changes were 
monitored using near UV CD spectroscopy. The spectra were acquired in the range of 320 – 
240 nm using a 10 mm quartz cuvette. The protein concentration used was 0.5 mg/ml.
Protein unfolding profiles were acquired at heating rates of 30, 60 and 120°C/hr with a 
holding time of 2 min every 5°C. A screw capped quartz cuvette was used to minimize loss 
of buffer due to evaporation. The sample was monitored for loss of volume before and after 
each thermal stress experiment. The temperature of the sample compartment was determined 
using a temperature probe that was inserted in the sample cell holder adjacent to the cuvette, 
as recommended by the manufacturer. The transition temperatures (Tm) for the unfolding 
profiles were determined by fitting the data to a sigmoid function using WinNonlin 
(Pharsight Corporation, Mountainview, CA):
[Eq 1]
where Yobserved is the ellipticity at 215 nm at any given temperature T, Ynative is the 
ellipticity value for the native state, Tm is the transition temperature, gamma (γ) is the hill 
coefficient, and Δm denotes the magnitude of the ellipticity change defined as (Ynative -
Yunfolded), where Yunfolded is the ellipticity value of the unfolded state. For all heating rate 
dependent studies, the data were normalized to account for variations in ellipticity values 
and represented as δθ (change in ellipticity) as a function of temperature. δθ was computed 
as θt-θnative, where θnative is the ellipticity of the protein in the native state and θt is the 
ellipticity at any given temperature. θnative was estimated by computing the mean ellipticity 
at initial temperatures.
Steady State Fluorescence Studies
Temperature dependent steady-state emission spectra were acquired using a PTI fluorometer 
(Photon Technology International, Lawrenceville, NJ) equipped with a Peltier unit. The 
samples were excited at 280 nm and the emission was monitored in the wavelength range of 
300 nm to 400 nm. The excitation and emission slits were set at 4nm. The excitation 
wavelength was shifted to lower wavelengths to evaluate the impact of scattering and Raman 
bands on the emission spectrum. Thermal stress studies were performed over the 
temperature range of 20–90°C. The data points were collected every 5°C with a holding time 
of ~2 minutes. The concentration of the protein was typically 10μg/ml. Path length of the 
quartz cuvette used was 1cm.
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Turbidity measurements were obtained with a Varian Cary 300 UV-Visible 
spectrophotometer fitted with a heating unit. 50 μg/ml samples of anti CD40 were added to 
screw capped quartz cuvettes and absorbance monitored at 350 nm. The temperature 
dependent changes in optical density were monitored over a temperature range of 25–90°C. 
Isothermal incubation studies were performed at 65° and 70°C and the aggregation of the 
protein was followed for 75 min.
Results
Effect of thermal stress on secondary structure
Thermal unfolding of the anti CD40 antibody was monitored by far UV CD spectroscopy to 
detect the temperature dependent changes in secondary structure of the protein. The far UV 
CD spectrum of the antibody showed a strong negative band around 217 nm and the 
spectrum show zero intensity at 206 nm, indicating that the protein predominantly existed in 
the beta sheet conformation, which is characteristic of immunoglobulin (Figure 2A). This is 
consistent with X-ray and molecular modeling studies for other immunoglobulins (4). As 
temperatures were increased to 60°C there were no significant changes observed in the 
spectral characteristics, indicating no substantial changes in secondary structural content 
over this temperature range. As the temperature is further increased from 60° to 75°C, 
substantial spectral changes were observed; a broadening and sharp increase in intensity 
(particularly >65°C) of the negative band was observed. Further increases in temperature 
(80–90°C) resulted in red shift with changes in spectral characteristics consistent with the 
formation of non-native beta sheet aggregates, as observed in the case of Factor VIII and 
alpha chymotrypsinogen (5, 6).
The melting profile generated based upon these spectral changes is shown in Figure 2B. 
Since ellipticity around 215 nm is characteristic of beta sheet structures, the temperature 
dependent spectral changes were followed at this wavelength. In the temperature range of 
20–60°C no ellipticity changes were observed. Further increase in temperature resulted in a 
decrease in ellipticity. Two distinct transitions were observed (indicated as I and II); one 
below and one above 70°C with the apparent Tm of this overall process observed around 
70°C. The two transitions were attributed to the semi-independent melting of structural 
domains within the Mabs and is consistent with the melting behavior observed for other 
immunoglobulins (7). In order to capture the peak broadening as a function of temperature, a 
second melting profile was generated following ellipticity changes at 230 nm. The ellipticity 
at this wavelength also decreased as a function of temperature, though the origin of this 
spectral broadening is not clear. It is possible that an increase in total beta content and/or a 
change in the environment of aromatic side chains occur as the protein is subjected to 
thermal stress. The melting profile generated at 230 nm is slightly different from that 
observed at 215 nm. For example, in the temperature range of 60 – 65°C, the ellipticity 
values decreased at 230 nm but did not change at 215 nm. As the temperature is increased 
above 65°C, substantial spectral changes were observed at both wavelengths. The data 
suggest that the conformational state of the protein at 65°C may represent a critical step in 
the unfolding process.
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Effect of thermal stress on tertiary structure
Changes in fluorescence emission spectra are generally taken to reflect changes in the 
tertiary structure of proteins as accessibility of fluorescent residues increases. Temperature 
dependent fluorescence spectra were acquired to investigate the effect of thermal stress on 
the tertiary structure of the antibody (Figure 3A). Since thermal inactivation of excited states 
leads to a loss of fluorescence intensity, shifts in emission maxima (peak position) were 
monitored as a function of temperature. At 20°C, the emission maxima was found to be 
around 330 nm with the maxima shifting to longer wavelength as the temperature was 
increased. An analogous form of [Eq 1] with λmax used in place of ellipticity values was 
applied (Figure 3B). The Tm based on tertiary structural alterations is slightly lower than 
that observed for secondary structural changes (Table 1). At 65°C, the protein lost 
substantial tertiary structural features but retained secondary structural elements as measured 
by far UV CD (spectral intensity at 215 nm)—behavior that is characteristic of molten 
globule intermediates (8, 9). However, ellipticity changes at 230 nm in far UV CD spectrum 
showed changes due to spectral broadening.
To get further insight into tertiary structural changes, thermal unfolding was also followed 
by near UV CD spectroscopy (Figure 3C). A meaningful estimation of the Tm could not be 
made due to the rapid aggregation at the higher concentration of protein (0.5 mg/ml) used in 
the near UV CD studies. It was useful, however, to determine conformational changes 
associated with unfolding of the protein. A negative band around 270 nm was observed for 
the anti CD40 antibody at 20°C that remained unaltered as the temperature increased to 
65°C, while ellipticity values below 250 nm decreased. This same pattern was also observed 
as broadening in far UV CD spectra (Figure 2) while the broadening appears more 
pronounced in Figure 3C because of the higher concentration used. The origin of this 
spectral change is not clear but could have contributions from both secondary and tertiary 
structural features. By 70°C the alterations in tertiary structure are readily apparent as 
indicated by the divergence of the profiles.
Effect of thermal stress on aggregation
Turbidity measurements have frequently been used to monitor the aggregation of proteins 
(10). Temperature dependent aggregation was monitored by measuring the optical density 
(O.D.) at 350 nm while heating the sample chamber (Figure 4A). The O.D. did not change 
as the temperature was increased up to 65°C, but further increase in temperature produced 
increases in turbidity, indicating aggregation. The data indicate that the transition observed 
using CD and fluorescence (Figure 2 and 3) is associated with the formation of aggregates.
To further investigate the formation and growth of oligomers, turbidity studies under 
isothermal incubation conditions were performed at 65°C and 70°C, a temperature range 
over which substantial conformational changes occurred as indicated by CD and fluorescent 
analysis. Incubation at 70°C caused the optical density values to increase in a time 
dependent manner (Figure 4B). The data suggests that there is an increase in aggregation as 
more aggregate prone monomer is incorporated into aggregated species. Comparatively 
smaller increase in optical density was observed for samples incubated at 65°C. It seems 
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likely that nucleation is initiated between 65°–70°C, since isothermal incubation at this 
temperature results in aggregate formation.
Aggregation Kinetics
The effect of aggregation kinetics on equilibrium unfolding of anti CD40 was evaluated by 
acquiring melting profiles at various heating rates as has previously been applied for other 
proteins (6, 7, 11). The transition temperature was found to be dependent on heating rate 
with the Tm increasing as the heating rate increased (Table 1). This could be described by 
the following relationship:
[Eq 2]
Where A is the frequency factor, Ea is the activation energy of the unfolding step, R is the 
gas constant, and ν is the heating rate. The activation energy for the transition was 
calculated using slope (−Ea/R) of a linear plot of ln (ν/Tm2) versus 1/Tm and found to be 
approximately 136 Kcal/Mole (r2 = 0.97). Such dependence demonstrates that the thermal 
unfolding is at least in part under kinetic control. It has been shown that the unfolding of 
several multi domain proteins including immunoglobulins, is a kinetically controlled process 
and interferes with the measurement and analysis of routine equilibrium unfolding events (6, 
7, 11) and the shape of the unfolding profile. It is possible that increase in size and a greater 
accumulation of aggregates occurs at lower heating rates. At higher heating rates, however, 
the protein reaches structurally disrupted and aggregated states more rapidly with minimal 
accumulation of aggregates of larger size. Similar conclusions were drawn for 
immunoglobulins by Vermeer and Norde and for recombinant Factor VIII (6, 7). The heating 
rate dependent size exclusion chromatography (SEC) data of FVIII showed that the position 
and intensity of the elution profiles were both dependent on this parameter.
Effect of protein concentration on aggregation
To investigate the effect of protein concentration on the aggregation of the antibody, we 
acquired melting profiles of the protein at higher concentration (400 μg/ml) at a 120°C/hr 
heating rate and compared it to the profile observed at lower concentration at the same 
heating rate (Figure 6). CD is an absorption measure and thus according to Beer’s law, 
should be linear with respect to concentration within the ideal detection range of the 
instrument. At lower concentration the CD ellipticity changed by 0.19 mdeg/μg/mL—the 
same as the transition for the higher concentration once the shorter path length is accounted 
for. This parameter is likely to be a measure of the relative population of monomer and 
aggregated species during transitions, suggesting that concentration does not at least initially 
alter the monomer population.
Over the lower temperature range, the melting profiles overlap. At higher temperatures, the 
melting profile demonstrates a stark divergence. Key difference between the profiles 
includes a rapid increase in ellipticity during/following the transition. At higher 
concentration, the aggregation kinetics occur at faster rate, thus the process of unfolding and 
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aggregation are not readily separable. The higher concentrations increase the potential for 
aggregation leading to a substantial alteration in the melting profile. Other factors that may 
alter the shape of the melting profile include loss of protein in the light path either from 
solvent evaporation and/or precipitation of the sample, but this was not observed here.
Effect of buffer species on aggregation
It has been shown that formulation variations such as buffer species can alter the stability of 
proteins and assessment of the impact of buffer species on protein stability is routinely 
examined during formulation development (12). We attempted to simulate a formulation 
condition of protein at pH 4 using acetate buffer due to its good buffering capacity in this 
range (2). The influence of buffer on unfolding and aggregation of the anti CD40 antibody 
was evaluated using CD to determine the ability of this technique to detect conformational 
changes, the rate of nucleation as well as growth and stability (Figure 7). Due to the 
temperature coefficient of the buffers employed (i.e., pH change /°C), pH changes may be 
elevated at higher temperatures. As an example, the pH of the acetate buffer changed by 0.14 
pH units as the temperature was raised from 20°C to 90°C. Furthermore, different buffer 
species were required to maintain pH at 4.0 and 7.0. The effects of the nature of the buffer 
cannot be separated from the effects of pH in the context of these experiments. The 
combined impact of buffering solute and pH is therefore interpreted as a general effect of 
buffer conditions. The Tm was measurable but dependent on the heating rate. A similar trend 
was observed for the antibody in PBS at pH 7.0 (Table 1). This suggests that even at low pH, 
the unfolding of the protein is still at least partially under kinetic control.
Discussion
The thermal unfolding of an anti CD40 antibody was monitored using far and near UV CD, 
fluorescence emission and turbidity measurements. Corroborating results obtained from 
temperature-dependent CD, fluorescence and turbidity measurements indicate that these 
biophysical techniques capture some key molecular events. As the protein is heated to 65°C, 
conformational changes occur (Figure 2 and 3), leading to the formation of oligomers. 
Further increases in temperature result in the growth of these aggregated species that are 
stabilized by conformational changes that result in the formation of inter-molecular beta 
strands. This conformational change is accompanied by the formation of aggregates as 
detected by increases in optical density (Figure 4B). Heating rate dependence studies 
showed that the unfolding of the protein is at least in part dependent upon the kinetics of the 
process (Figure 5), while concentration dependent studies showed that the aggregation of the 
protein is more pronounced at higher concentration (Figure 6). Since aggregation depends 
on formulation conditions, studies with various buffers and formulations can impact the 
shape of the melting profile. Overall, the unfolding of the Mab appears to be controlled by 
both equilibrium unfolding involving conformational changes and by aggregation kinetics, 
involving the rate of nucleation and growth of the aggregates. It is possible that either of 
these steps can be rate limiting depending on experimental conditions. Therefore, the utility 
of Tm in predicting long-term stability and shelf-life is low since it does not take into 
account the subsequent aggregation kinetics that interfere with equilibrium unfolding 
measurements. We propose that in addition to Tm, several other parameters should also be 
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taken into account as predictors of stability. The formation and kinetics of aggregation prone 
conformational state (as observed at 65°C) may be useful for predicting stability and shelf-
life. The spectral characteristics of this conformational state is native like but with some 
detectable differences; a broader far UV CD spectrum with a small red shift in the 
fluorescence emission maxima. Further, the shape of the melting profile and its heating rate 
dependence both provide insight into aggregation kinetics and their impact on equilibrium 
unfolding. We propose that this may be of significance, since stability and shelf-life may not 
only defined or be reflected by equilibrium unfolding but may also be a function of 
aggregation kinetics which are expected to be more pronounced at higher concentration.
Roberts and his colleagues have elegantly analyzed the unfolding and kinetics of the 
aggregation of alpha-chymotrypsinogen using a LENP model (13). The model proposed here 
is based on LENP to define key steps involved in the unfolding of this Mab (Figure 1).
The initial monomer (native state) undergoes conformational changes in the temperature 
range of 50° to 65°C. These conformational changes may represent either the Fc or Fab 
portions of the antibody. It has been shown that for murine Mabs the first transition 
corresponds to the Fc portions while in the same humanized immunoglobulins the Fab 
region is altered first (7, 14). This conformational change may represent an aggregation 
prone state(s) and to initiate oligomerization events. The formation of this conformational 
state and subsequent kinetics may be critical to the stability of the protein. Further thermal 
stress (between 65°C and 70°C) results in the formation of small protein clusters. It is 
probable that these oligomers are transient and cannot be detected using time-averaged 
analytical techniques such as SEC. Multiple orthogonal techniques, such as CD and turbidity 
measurements, however, may be used to infer the presence of these key kinetic 
intermediates. As seen by turbidity measurements, there is a difference in aggregation 
kinetics between samples incubated at 65°C and 70°C, suggesting that the formation of both 
kinetic intermediate states and nucleation occur in this temperature range. Irreversible 
conformational rearrangements lead to nucleation (which may have unqiue signatures in CD 
spectra. The oligomerization can also constitute a reversible growth phase as more native 
like monomers are added to the oligomers (Figure 1). The growth phase involves addition 
and rearrangement of aggregation prone monomers at 70°C and above that result in the 
formation of soluble high molecular weight aggregates. During this stage, conformational 
changes such as the formation of intermolecular beta strands are observed as seen in CD 
spectra (figure 2A). This is corroborated by turbidity measurements that show substantial 
increase in optical density. The kinetics of this stage determines the shape of the melting 
profile. If the rate is faster due to higher protein concentration or solution conditions such as 
buffer species, it is likely that the trend observed in the melting profiles would manifest as 
increases in spectral intensity with temperature. This type of spectral change is a common 
feature of aggregating proteins which form intermolecular beta-structure (15). Assembly of 
aggregates and/or condensation occurs leading to the formation of bundles and filaments. 
This stage requires a threshold aggregate size, which is a function of the nucleation and 
growth phases of the model. These phases are not well described by the analytical 
techniques employed here owing to a lack of suitable analytical techniques that can 
quantitatively describe sub visible particles (16).
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The model based helps to dissect the melting profile of this antibody and to better 
understand the nature of the molecular level changes that occur during unfolding. Any 
changes in any portion of the melting profile as function of formulation variations would 
give an insight into the molecular level details on the impact of that excipient on unfolding. 
For example, the melting profile during and after transition captures nucleation and growth 
phase of aggregation, respectively. Since Mabs often share common molecular, 
conformational and folding characteristics, this model based on Lumry-Eyring nucleated 
polymerization model combined with appropriate spectroscopic measurements provides a 
rational approach to aid in the formulation development of Mabs and could be used in 
screening formulation buffers and excipients as well as for clonal selection. Furthermore, 
according to this model, the loss of monomer and rate of aggregation are important factors 
that should define protein stability and shelf life. These two factors depend critically on 
formulation conditions such as initial protein concentration, conformational changes, 
aggregate size, and rate of nucleation and growth.
Applicability of the approach
The authors suggest the following experimental approach could be employed to aid in the 
formulation development and stability testing of Mabs: (i) Conformational analysis under 
thermal stress at lower protein concentration (under these experimental conditions it is 
assumed that the contribution of aggregation kinetics is minimal) using CD and fluorescence 
spectroscopy. The melting profile generated helps to understand equilibrium unfolding and 
the role of thermodynamics in the process. Furthermore, these techniques can also identify 
aggregation prone states during unfolding. If the process is reversible, calculation of 
thermodynamic parameters may be usefully obtained. Differential scanning calorimetry 
(DSC) could also be employed to this end. (ii) Turbidity measurement performed with lower 
concentration samples under thermal stress to determine the conditions under which 
aggregates are formed. Since turbidity can also indicate phase separation and is highly 
concentration dependent, this could also be replaced by other techniques. Nephelometery 
and right angle light scattering measurements during fluorescence analysis are potentially 
more sensitive methods. Comparing the melting profile generated using turbidity or other 
light scattering based measurements with that generated using CD experiments provide 
information regarding the conformational changes associated with formation of aggregates. 
FTIR may also be used for the same purpose. (iii) Heating rate dependent studies should be 
employed to evaluate the contribution of aggregation kinetics. Using this data, the activation 
energy for the aggregation kinetics can be estimated. (iv) Turbidity and CD spectral studies 
under isothermal incubation conditions at various temperatures provide information on 
nucleation and growth stage of the aggregates. (v) The melting profile using thermal stress at 
various (higher) concentrations of the protein provides information about the effect of 
concentration on the shape of the melting profile. Maintaining optical density within proper 
limits with the use of shorter path length and screw capped cuvettes to avoid evaporation are 
some of the precautions that must be taken while analyzing samples at higher concentration. 
Heating rate dependence at higher concentration of the sample is useful for estimating 
increases in the rate of aggregation and its effect on equilibrium unfolding. (vi) Application 
of the folding model to understand protein behavior under unfolding conditions and 
comparison of several formulation variations gives insight into the role of excipients on the 
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aggregation of the protein that is controlled both by equilibrium unfolding and by 
aggregation kinetics(13).
Conclusions
Overall, this experimental approach combined with folding model has the potential to be an 
important tool during the formulation development of Mabs and analysis of their stability. 
The approach also identifies an aggregation prone conformational state. Monitoring the 
formation and kinetics of this conformational change would provide insight into the stability 
and possibly help to predict the shelf-life of the protein. Furthermore, automation of these 
techniques to permit measurement of multiple samples simultaneously makes it an attractive 
approach for high throughput formulation development for buffer species selection, 
screening for other excipients and for clonal selection. Proteins produced by multiple clones 
can be compared for stability, providing information to detect those clones that produce 
soluble aggregates. The nucleation and growth phase of these clones would distort melting 
profiles due to increased rate of nucleation and aggregate growth. In addition, understanding 
the key steps and molecular changes during unfolding would in aid rational formulation 
development and in the identification of stabilizing excipients by facilitating their 
optimization.
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Folding model based on Lumry-Eyring nucleated polymerization model (LENP). Native, 
intermediate and oligomer formation are reversible processes with nucleation and 
subsequent steps representing irreversible events (LENP). In addition, the oligomer 
formation may not involve formation of intermediate states and larger aggregates may also 
dissociate back to oligomers.
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Temperature dependent changes in secondary structure of an anti CD40 antibody Figure 2A: 
The far UV CD spectra of anti CD40 antibody (in PBS at pH 7.0), as a function of 
temperature. Figure 2B: Melting profile of anti CD40. Secondary structure transition of the 
Mab was monitored at 215 nm and 230nm while heating the protein at a rate of 60°C/hr.
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Temperature dependent changes in tertiary structure of the anti CD40 antibody; Figure 3A: 
Fluorescence emission spectra of the anti CD40 antibody as a function of temperature. The 
sample was excited at 280 and emission monitored from 300–400 nm. The peak at 308 nm is 
a water Raman band while the secondary peak in the 330–340 nm range is of primary 
interest. Figure 3B: Melting profile generated using the peak maxima data in Figure 3A. The 
solid lines represent the fit obtained using a modified version of [Eq 1]. Figure 3C: 
Temperature dependent changes in near UV CD spectrum of the anti CD 40 antibody.
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Temperature dependent changes in aggregation of the anti CD40 antibody as measured by 
turbidity. Figure 4A: The optical density (OD) was monitored at 350 nm as a function of 
temperature at the two heating rates of 60°C/hr and 120 °C/hr. The concentration of the 
protein used was 50μg/ml. Figure 4B: Isothermal incubation studies performed at 65°C and 
70°C. The optimal density at 350 nm was followed for 75 min.
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Heating rate dependence of the thermal unfolding of the anti CD40 antibody. The secondary 
structure transition of the protein was monitored with far UV CD at 215 nm over the 
temperature range of 20 – 90°C at different heating rates.
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The effect of concentration on the thermal unfolding of the anti CD40 antibody. The sample 
was subjected to thermal stress in the temperature range of 20°C to 90°C at a heating rate of 
120°C/hr. The concentration of the sample used was 400 μg/ml in a 1 mm cuvette. Data 
from the melting profile of protein at 20 μg/ml in a 10 mm cuvette at the same heating rate 
(Figure 5) is replicated for reference.
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The effect of buffer conditions on the thermal unfolding of the anti CD40 antibody in acetate 
buffer at pH 4.0. The sample was subjected to thermal stress in the temperature range of 
20°C to 90°C at heating rates of 30, 60 and 120°C/hr.
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Table 1
Thermal stress and phase transition of anti CD40 antibody as a function of heating rate (SE corresponds to fit 
error).
Instrumentation Buffer pH (Initial) Heating Rate (°C/hr) Tm ± S.E. (°C)
Fluorescence PBS 7.0 60 64.5 ± 0.6
CD PBS 7.0 30 68.3 ± 0.4
CD PBS 7.0 60 69.1 ± 0.3
CD PBS 7.0 120 70.5 ± 0.8
CD Acetate 4.0 30 68.1 ± 1.8
CD Acetate 4.0 60 69.1 ± 1.4
CD Acetate 4.0 120 70.4 ± 2.0
J Pharm Sci. Author manuscript; available in PMC 2016 November 22.
